<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03078933</url>
  </required_header>
  <id_info>
    <org_study_id>ORI-16-003</org_study_id>
    <nct_id>NCT03078933</nct_id>
  </id_info>
  <brief_title>A Feasibility Study of Advance Plasma Therapy001 Plasma/Nitric Oxide Therapy for the Treatment of Diabetic Foot Ulcers</brief_title>
  <official_title>A Randomized, Prospective, Multi-Center Feasibility Study of APT001 Plasma/Nitric Oxide Therapy for the Treatment of Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Origin Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Origin Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical trial will assess the delivery of Nitric Oxide topically to the diabetic foot
      ulcer wound and the surrounding wound area as it related to wound healing.

      The objective of the study is to assess the Nitric Oxide Therapy treatment time (the number
      of minutes to deliver the treatment) and frequency (number of days per week to treat) to
      determine the most optimal treatment time and frequency to develop a rationale for safety and
      efficacy for the final APT001 clinical study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      APT001 is a medical device that generates nitric oxide (NO) from ambient room air within a
      defined plasma stream. This study is a randomized, prospective, multi-center feasibility
      study that will assess the effect of Nitric Oxide treatment time (minutes) and frequency
      (days/week) on wound healing in adults with diabetic foot ulcers (DFUs) and to provide
      information that will be used to develop final safety and effectiveness hypotheses for a
      pivotal trial of the APT001 device.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2017</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Two or more interventions, each alone and in combination, are evaluated in parallel against a control group</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Investigator will be blinded to photgraphs and punch biopsy results</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Wound Closure rate</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>cm2 of epithelium coverage per week</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care for diabetic foot ulcer wound care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APT001NitricOxide tx 2x week 6 min+ SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APT001 Nitric OxideTherapy 2x week for 6 min. treatment time plus standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APT001Nitric Oxide tx 2x week 12 min+SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APT001Nitric Oxide Therapy 2x week for 12 min. treatment time plus standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APT001Nitric Oxide tx 4x week 6 min+SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APT001 Nitric Oxide Therapy 4x week for 6 min. treatment time plus standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APT001Nitric Oxide tx 4x week 12 min+SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APT001Nitric Oxide Therapy 4x week for 12 min. treatment time plus standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard of Care arm which includes wound care, dressings and debridement.</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nitric Oxide Therapy 2x week 6 min. plus standard of care</intervention_name>
    <description>Active Therapy Nitric Oxide delivered topically to the wound twice a week for 6 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.</description>
    <arm_group_label>APT001NitricOxide tx 2x week 6 min+ SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nitric Oxide Therapy 2x week 12 min. plus standard of care</intervention_name>
    <description>Active Therapy Nitric Oxide delivered topically to the wound twice a week for 12 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.</description>
    <arm_group_label>APT001Nitric Oxide tx 2x week 12 min+SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nitric Oxide Therapy 4x week 6 min. plus standard of care</intervention_name>
    <description>Active Therapy Nitric Oxide delivered topically to the wound four times a week for 6 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.</description>
    <arm_group_label>APT001Nitric Oxide tx 4x week 6 min+SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nitric Oxide Therapy 4x week 12 min. plus standard of care</intervention_name>
    <description>Active Therapy Nitric Oxide delivered topically to the wound four times a week for 12 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.</description>
    <arm_group_label>APT001Nitric Oxide tx 4x week 12 min+SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes Type 1 or Type 2

          -  Wound size greater than or equal to 1 cm2 and less than or equal to 16 cm2

          -  HbA1c less than or equal to 12 %

          -  Single full thickness DFU on the plantar aspect of toes or foot

          -  Ankle Brachial Index greater than or equal to 0.7

        Exclusion Criteria:

          -  Infection of the ulcer

          -  Active Charcot's disease

          -  wound involves deeper tissues including bone or tendon

          -  Negative pressure therapy on affected foot or Hyperbaric Oxygen Therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Dantzker, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Origin Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Terry Treadwell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Advanced Wound Care</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katherine M Tranotti, BSN/MBA</last_name>
    <phone>6092506000</phone>
    <phone_ext>6006</phone_ext>
    <email>ktranotti@originww.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Pelka</last_name>
    <phone>6092506000</phone>
    <phone_ext>6007</phone_ext>
    <email>ppelka@originww.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85634</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93721</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <zip>91342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Cooper City</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33031`</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>78245</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2017</study_first_submitted>
  <study_first_submitted_qc>March 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2017</study_first_posted>
  <last_update_submitted>June 5, 2017</last_update_submitted>
  <last_update_submitted_qc>June 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DFU</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

